To the Editor: Thomas and colleagues1 describe the ethical complexities that can arise in the use of non‐invasive prenatal testing (NIPT) based on the detection of cell‐free fetal DNA in the maternal circulation to screen for chromosomal and other genetic fetal conditions, especially if the clinical utility and implications of the testing are not well understood and explained. They indicate that “the current NIPT tests available are for specific chromosomal aneuploidy, extended panels of targeted conditions and low resolution whole genome sequencing”.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
No relevant disclosures.